Sarepta Therapeutics (NASDAQ: SRPT) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Sarepta Therapeutics to similar companies based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Valuation and Earnings

This table compares Sarepta Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sarepta Therapeutics $56.77 million -$229.47 million -24.05
Sarepta Therapeutics Competitors $263.26 million $68.25 million -6.44

Sarepta Therapeutics’ competitors have higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Sarepta Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sarepta Therapeutics -112.08% -62.44% -51.53%
Sarepta Therapeutics Competitors -5,492.74% -451.92% -42.73%

Institutional and Insider Ownership

65.5% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.6% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Sarepta Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics’ competitors have a beta of 6.66, indicating that their average stock price is 566% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sarepta Therapeutics and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics 0 4 15 0 2.79
Sarepta Therapeutics Competitors 766 3051 11239 227 2.71

Sarepta Therapeutics presently has a consensus price target of $65.61, suggesting a potential upside of 33.06%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.83%. Given Sarepta Therapeutics’ competitors higher probable upside, analysts clearly believe Sarepta Therapeutics has less favorable growth aspects than its competitors.

Summary

Sarepta Therapeutics competitors beat Sarepta Therapeutics on 7 of the 12 factors compared.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.